Natera's Signatera wins Japan approval for colorectal cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St futures ease as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges higher against euro
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
June 24, 2026 3:00 AM EDTFirst PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant setting
Commercial launch expected by year-end, pending final reimbursement and pricing
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today... More
